

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from Thursday 27th July 2017**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)	✓	Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Richard Harris – LPC Representative	✓
		Mr Andrew Houston - Senior Mental Health Pharmacist		Mr M Ahmed - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)	✓			<u>DBTHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Mrs Heidi Atkinson- Non Medical Prescriber Representative (RDaSH DCIS)	✓	Mr Andrew Barker – Chief Pharmacist DBTHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBTHFT	✓
Mr Rob Wise – Head of Medicines Management (BCCG)	✓	<u>Doncaster LMC</u>		Dr Mahmoud Al Khoffash – Medical Director representative DBTHFT	✓
		Dr Dean Eggitt - LMC Secretary			
		Mr David Gibbons - LMC Deputy		<u>FCMS (When necessary)</u>	
	✓	Dr Rमित Shah – LMC Chair	✓	Mrs Nicola Sanders Mrs Tracey Edwards Mrs Alison O'Conner	

Minutes Only :- Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

**Dr Rupert Suckling & Mr Victor Joseph DMBC
Mrs Nicola Sanders & Mrs Tracey Edwards FCMS**

**In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)
Mr John Bane - Deputy Chief Pharmacist DBTHFT**

Agenda Item	Discussion Points	Action By
07/17/1	Apologies Apologies were received from Dr D Eggitt	
07/17/2	Declarations of Interest, Gifts or Hospitality Declarations were received from: Dr R Sykes has recently chaired a meeting sponsored by Astra Zeneca Ltd. Mr R Harris has received a one off payment from Napp Pharmaceuticals for speaking at a meeting. Dr R Shah is associated with Optimum Healthcare & the Primary Care Federation	

07/17/3	<p>Minutes of last meeting</p> <p>The minutes of the last meeting held on the 11th May 2017 were agreed as a true and accurate record and will be made available on the medicines management website.</p>	
07/17/4.1	<p>Matters Arising</p> <p>The Chair announced the recent departure of Mr M Randerson as the Head of Medicines Management at Doncaster CCG. An acknowledgement of the vast amount of work and time committed to this Committee and other groups on behalf of the Committee was given. Mark was wished well for the future.</p>	
04/17/1.1	<p>Non- Medical Prescriber Representative recruitment</p> <p>The recruitment has been successful and Mrs Heidi Atkinson was welcomed to the meeting by the Committee.</p>	
11/15/8.4	<p>Potential development of SCP/Pathway update for the management of ADHD in adults, young people and children.</p> <p>The Shared Care Protocol (SCP) is in a position to be considered by the Committee, although progression now depends on how the pathway of care is defined. The Committee agreed that until the pathway is formalised the SCP will not go live. NHSD-MMT will speak with Mrs E Gordon to request that this moves forward as quickly as possible. NHS-B confirmed that there has been discussion in Bassetlaw around the development of a SCP in the Nottinghamshire area, further updates will be shared. RDaSHFT will share the draft SCP paperwork at the August meeting.</p>	<p>RDaSHFT</p> <p>NHSD-MMT(GB)</p> <p>NHS-B</p>
10/16/8.2	<p>Parkinson's disease – SCP</p> <p>The paperwork will be available at the August meeting</p>	RDaSHFT
03/17/8.4	<p>Ulipristal Acetate 5mg</p> <p>The Committee discussed the Rotherham guidance document and was advised that all the Obstetrics and Gynaecology Department were in agreement for its use. The Committee asked that DBTHFT obtained the final document from Rotherham to amend it to suit Doncaster and then return to the Committee for approval.</p>	DBTHFT
04/17/8.1	<p>Dalteparin SCP</p> <p>The paperwork will be available for approval at the August meeting.</p>	DBTHFT
05/17/8.1	<p>Draft Amber G Guidance document for Midodrine for patients with postural hypotension</p> <p>The Committee was presented with the amended document and was advised of a further amendment around the annual monitoring of blood pressure in Primary Care (lying & standing BP not being required). On completion of this change the Committee approved the document and the categorisation of midodrine on the TLS can therefore be changed to Amber G. The document will be made available on the medicines management website.</p>	NHSD-MMT(AM)

05/17/8.4	<p>Thyroid Register DCCG Clinical Reference Group has discussed the potential safety issues arising due to the cessation of the thyroid register that has been held by DBTHFT. There was agreement that a large number of patients do not need to be managed in Secondary Care. There are certain cohorts of patients that will be still managed in Secondary Care including patients:</p> <ul style="list-style-type: none"> • taking long term carbimazole • taking amiodarone • with hypoparathyroidism & hyperparathyroidism • with thyroid cancer <p>Discussions regarding Primary Care workload are being held outside of the APC meeting. Further clarity on the situation will be requested by NHSD-MMT</p>	NHSD- MMT (GB)
07/17/5	<p>Traffic Light – Drugs for Review All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter. Triptorelin (Decapeptyl) used in breast cancer remains as Grey 4 pending further discussion at DBTHFT Eluxadoline (Truberzi) used in irritable bowel syndrome with diarrhoea has been categorised as Amber G (refer to formulary) Lenalidomide (Revlimid, Celgene) is now licensed in multiple myeloma in people who have undergone autologous stem cell transplantation and is categorised as Red 1. Nepafenac (Nevanac) is now licensed in the reduction of postoperative macular oedema associated with cataract surgery in diabetic patients and is categorised as Red 1. Ibrutinib (Imbruvica) remains Red for mantle cell lymphoma and Grey 2 for chronic lymphocytic leukaemia.</p>	NHSD- MMT(AM)
07/17/6	<p>APC Officers actions All officers actions were agreed as proposed, will be updated on the traffic light system.</p>	NHSD- MMT(AM)
07/17/7	<p>Traffic Light – Additions for Consideration All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter. Follitropin delta (Rekovelle) used in IVF has been categorised as Red1,2 Bezlotoxumab (ZINPLAVA) used in clostridium difficile infection has been categorised as Red 1,2 Magnesium glycerophosphate (Neomag, MagnaPhos Range, Mag-4 & LiquaMag GP) brands have been added to TLS entry & the category is Amber-G Nusinersen (Spinraza) used in spinal muscular atrophy has been categorised as Red 1,2,3 Blephaclean and associated preparations have been categorised as Grey 2</p>	NHSD- MMT(AM)
07/17/8	<p>New Business</p>	

07/17/8.1	<p>Deputy Chair position The position of deputy chair held by Mr M Randerson will be temporarily filled by Mrs G Bradley.</p>	
07/17/8.2	<p>Shared Care Protocol for the use of oral N-Acetylcysteine (NAC) in the management of Idiopathic Pulmonary Fibrosis in Adults The routine review of the SCP was approved by the Committee and the new paperwork will be available on the medicines management website.</p>	NHSD- MMT(AM)
07/17/8.3	<p>Fosfomycin 3g oral sachets The guidance document for the prescribing and dispensing of fosfomycin was discussed by the Committee. The process of obtaining the drug will be changed to indicate that community pharmacy will be the first option for the dispensing of the drug and DBTHFT main dispensary to be used if problems arise over weekend/bank holiday periods. The changes will be communicated via APC Committee members to individual organisations and the medicines management newsletters. NHSD –MMT will check PPA data to confirm how often the drug has been requested. The updated document will be available on the medicines management website.</p>	NHSD- MMT(GB) All NHSD- MMT(AM)
07/17/8.4	<p>Methylphenidate XL tablets / Concerta XL – possible review/switch to cost effective alternative branded generic. The Committee was asked for a clinical opinion on the decision Sheffield CCG has made to switch Methylphenidate MR preparations from one branded generic to another. Following discussion the Committee were in agreement that clinically this was acceptable. It was however agreed that there are other issues to consider when undertaking these switches that are not the responsibility of this Committee.</p>	
07/17/8.5	<p>Updated Rheumatology Conditions SCP The Committee was presented with updated paperwork to consider, the key changes included:</p> <ul style="list-style-type: none"> • Updated monitoring in accordance to BSR DMARD monitoring guidelines 2017 • Shared care prescription and monitoring for mycophenolate mofetil and subcutaneous methotrexate. • The duration of stable dose before GPs take over prescription is defined. <p>The Committee approved the document with the exception of the move from methotrexate injection from Red to Amber status. The reason for this was directly linked to an issue with the Local Authority (LA) around waste collection.</p> <p>Mr Bane requested the contact name at the LA to contact regarding the waste collection as he would contact them to request a speedy resolution to the current issues.</p> <p>It was agreed that the SCP would be amended to remove the methotrexate injection change and then will be made available on the medicines management website.</p>	NHSD- MMT(GB) NHSD- MMT(AM)

	Once the waste collection issue had been resolved the SCP can return to the APC for re-consideration of the traffic light status of methotrexate injection.	
07/17/8.6	Transgender Prescribing Guidelines The Committee was made aware of the NHS England public consultation on proposals for new service specifications that, if adopted, describe how specialised gender identity services for adults will be commissioned and delivered. All represented organisations were asked to respond to the consultation. DCCG will be responding. The consultation will close on 30 th September 2017.	All
07/17/8.7	Regional Medicines Optimisation Committee NHSD-MMT provided an update on the progress of the Committee. There is a representative from Yorkshire and Humberside on the Committee. The proposed themes for work streams are: <ul style="list-style-type: none"> • Biosimilar medication • Antimicrobial resistance • Polypharmacy The Committee will be made aware of any further updates.	
07/17/9	DBTHFT D&TC Update The minutes of the meeting held in May 2017 were received by the Committee	
07/17/10	Formulary Liaison Group Update No minutes available	
07/17/11	Doncaster Prisons Drug & Therapeutic Committee No minutes available	
07/17/12	RDASH FT & Medicines Management Committee Update The minutes of the meeting held in April & May 2017 were received by the Committee	
07/17/13	Barnsley Area Prescribing Committee Update No minutes available	
07/17/14	Rotherham Area Prescribing Committee Update The minutes of the meeting held in March & May 2017 were received by the Committee	
07/17/15	Sheffield Area Prescribing Committee Update The minutes of the meeting held in April 2017 were received by the Committee	
07/17/16	Nottinghamshire Area Prescribing Committee Update The minutes of the meeting held in March 2017 were received by the Committee	
07/17/17	Any Other Business No other items of business were received	
07/17/18	Date, time & venue of next meeting 12 noon prompt Thursday 31 st August 2017 in Meeting Room 3 Sovereign House	
	12 noon prompt Thursday 28 th September 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 26 th October 2017 in Meeting Room 3 Sovereign House 12 noon prompt Thursday 30 th November 2017 in Meeting Room 3 Sovereign House No December meeting 12 noon prompt Thursday 25 th January 2018	

	<p>in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 22nd February 2018 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th March 2018 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 26th April 2018 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 31st May 2018 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 28th June 2018 in Meeting Room 3 Sovereign House</p>	
--	---	--